OBJECTIVES: This study was conducted to determine if pulmonary metastasectomy (PM) for isolated pancreatic cancer metastases is safe and effective. METHODS: This was a retrospective case-control study of patients undergoing PM at our institution from 2000 to 2009 for isolated lung metastasis after resection for pancreatic cancer. Clinical and pathologic data were compared with a matched reference group. Resected neoplasms were immunolabeled for the Dpc4 protein. Kaplan-Meier analysis compared overall survival and survival after relapse. RESULTS: Of 31 patients with isolated lung metastasis, 9 underwent 10 pulmonary resections. At initial pancreas resection, all patients were stage I or II. Other baseline characteristics were similar between the two groups. Median time from pancreatectomy to PM was 34 months (interquartile range 21-49). During the study, 29/31(90.6%) patients died. There were no in-hospital mortalities or complications after PM. Median cumulative survival was significantly improved in the PM group (51 vs. 23 months, p = 0.04). There was a trend toward greater 2-year survival after relapse in the PM group (40% vs. 27%, p = 0.2). CONCLUSIONS: In patients with isolated lung metastasis from pancreatic adenocarcinoma, this is the first study to show that pulmonary resection can be performed safely with low morbidity and mortality. The improved survival in the PM group may result in part from selection bias but may also represent a benefit of the procedure.
OBJECTIVES: This study was conducted to determine if pulmonary metastasectomy (PM) for isolated pancreatic cancer metastases is safe and effective. METHODS: This was a retrospective case-control study of patients undergoing PM at our institution from 2000 to 2009 for isolated lung metastasis after resection for pancreatic cancer. Clinical and pathologic data were compared with a matched reference group. Resected neoplasms were immunolabeled for the Dpc4 protein. Kaplan-Meier analysis compared overall survival and survival after relapse. RESULTS: Of 31 patients with isolated lung metastasis, 9 underwent 10 pulmonary resections. At initial pancreas resection, all patients were stage I or II. Other baseline characteristics were similar between the two groups. Median time from pancreatectomy to PM was 34 months (interquartile range 21-49). During the study, 29/31(90.6%) patients died. There were no in-hospital mortalities or complications after PM. Median cumulative survival was significantly improved in the PM group (51 vs. 23 months, p = 0.04). There was a trend toward greater 2-year survival after relapse in the PM group (40% vs. 27%, p = 0.2). CONCLUSIONS: In patients with isolated lung metastasis from pancreatic adenocarcinoma, this is the first study to show that pulmonary resection can be performed safely with low morbidity and mortality. The improved survival in the PM group may result in part from selection bias but may also represent a benefit of the procedure.
Authors: Jussuf T Kaifi; Niraj J Gusani; Isabelle Deshaies; Eric T Kimchi; Michael F Reed; Rickhesvar P Mahraj; Kevin F Staveley-O'Carroll Journal: J Surg Oncol Date: 2010-08-01 Impact factor: 3.454
Authors: J R Headrick; D L Miller; D M Nagorney; M S Allen; C Deschamps; V F Trastek; P C Pairolero Journal: Ann Thorac Surg Date: 2001-03 Impact factor: 4.330
Authors: Erlinda E Embuscado; Daniel Laheru; Francesca Ricci; Ki Jung Yun; Sten de Boom Witzel; Allison Seigel; Katie Flickinger; Manuel Hidalgo; G Steven Bova; Christine A Iacobuzio-Donahue Journal: Cancer Biol Ther Date: 2005-05-12 Impact factor: 4.742
Authors: Cristina R Ferrone; Michael W Kattan; James S Tomlinson; Sarah P Thayer; Murray F Brennan; Andrew L Warshaw Journal: J Clin Oncol Date: 2005-10-20 Impact factor: 44.544
Authors: Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru Journal: J Clin Oncol Date: 2009-03-09 Impact factor: 44.544
Authors: Mark W Onaitis; Rebecca P Petersen; John C Haney; Leonard Saltz; Bernard Park; Raja Flores; Nabil Rizk; Manjit S Bains; Joseph Dycoco; Thomas A D'Amico; David H Harpole; Nancy Kemeny; Valerie W Rusch; Robert Downey Journal: Ann Thorac Surg Date: 2009-06 Impact factor: 4.330
Authors: Ryan M Thomas; Mark J Truty; Graciela M Nogueras-Gonzalez; Jason B Fleming; Jean-Nicolas Vauthey; Peter W T Pisters; Jeffrey E Lee; David C Rice; Wayne L Hofstetter; Robert A Wolff; Gauri R Varadhachary; Huamin Wang; Matthew H G Katz Journal: J Gastrointest Surg Date: 2012-05-30 Impact factor: 3.452
Authors: Yi Zhong; Anne Macgregor-Das; Tyler Saunders; Martin C Whittle; Alvin Makohon-Moore; Zachary A Kohutek; Justin Poling; Brian T Herbst; Breanna M Javier; Leslie Cope; Steven D Leach; Sunil R Hingorani; Christine A Iacobuzio-Donahue Journal: Clin Cancer Res Date: 2016-09-16 Impact factor: 12.531
Authors: Tamna Wangjam; Zhe Zhang; Xian Chong Zhou; Laxmi Lyer; Farzana Faisal; Kevin C Soares; Elliott Fishman; Ralph H Hruban; Joseph M Herman; Daniel Laheru; Matthew Weiss; Min Li; Ana De Jesus-Acosta; Christopher L Wolfgang; Lei Zheng Journal: Oncotarget Date: 2015-11-03
Authors: Stephanie Downs-Canner; Mazen Zenati; Brian A Boone; Patrick R Varley; Jennifer Steve; Melissa E Hogg; Amer Zureikat; Herbert J Zeh; Kenneth K W Lee Journal: J Surg Oncol Date: 2015-07-07 Impact factor: 3.454
Authors: Brian A Boone; Herbert J Zeh; Brady K Mock; Paul J Johnson; Igor Dvorchik; Ken Lee; A James Moser; David L Bartlett; J Wallis Marsh Journal: HPB (Oxford) Date: 2013-04-22 Impact factor: 3.647